Section Arrow
LYEL.NASDAQ
- Lyell Immunopharma Inc
Quotes are at least 15-min delayed:2025/09/12 04:14 EDT
Pre Market
Last
 --
-- (--)
Bid
8.8
Ask
13.3
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 13.3
+0.23 (+1.76%)
Day High 
13.49 
Prev. Close
13.07 
1-M High
13.5 
Volume 
37.48K 
Bid
8.8
Ask
13.3
Day Low
12.59 
Open
13.22 
1-M Low
9.28 
Market Cap 
251.09M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.94 
20-SMA 11.36 
50-SMA 10.88 
52-W High 32 
52-W Low 7.65 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-24.26/-13.97
Enterprise Value
302.08M
Balance Sheet
Book Value Per Share
15.56
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
61.00K
Operating Revenue Per Share
2.52
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GRIGRI Bio Inc.2.05+0.49+31.41%0.02PE
Pre Market 1.78 -0.27 -13.17%
RXRXRecursion Pharmaceuticals4.85+0.31+6.83%-- 
Pre Market 4.93 +0.08 +1.65%
SLXNSilexion Therapeutics Corp4.93+0.445+9.92%-- 
Pre Market 4.92 -0.01 -0.20%
ADAPAdaptimmune Therapeutics plc0.0505-0.0003-0.59%-- 
Pre Market 0.0515 +0.001 +1.98%
ROIVRoivant Sciences Ltd14.41+0.64+4.65%1.95PE
Pre Market 14.41 0 0.00%
Quotes are at least 15-min delayed:2025/09/12 04:14 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.